Daniel Gilbert

Reporter Covering The Business Of Medicine

AS SEEN ON

Preston's Summary

Daniel Gilbert is a Reporter Covering The Business Of Medicine at The Washington Post. He specializes in topics such as aging and longevity, diet and nutrition, gene therapy, immunotherapy, and pharmaceutical manufacturing, while also addressing themes related to family and relationships, particularly in the context of wellness programs and remote healthcare. His work has been featured in numerous publications, including the Anchorage Daily News, The Seattle Times, and The Boston Globe.

Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston

Geo Focus

United States (National)

Coverage Attributes:

Beta
Informative: 59 %
Data Driven: 24 %
Events: 5 %
Interviews Q&as: 3 %
Reviews: 2 %

Themes Covered:

Not enough data icon

Not enough data

Most Recent Topics:

  • Aging & Longevity
  • Diet & Nutrition
  • Gene Therapy
  • Immunotherapy
  • Oncology
  • Pharmaceutical Manufacturing
  • Remote Healthcare
  • Wellness Programs

Pitching Insights

Daniel Gilbert's coverage revolves around the healthcare and pharmaceutical industries, with a focus on FDA announcements, legal policy regulation, and investment analysis. He frequently cites data to support his reporting.

For effective outreach to Daniel, consider providing insights into FDA approvals or rejections of new drugs, in-depth analyses of pharmaceutical companies' financial performance or strategic moves, and perspectives on the impact of regulatory changes on the healthcare industry. Expert commentary from professionals deeply involved in drug development processes or those with regulatory expertise would likely be well-received.

Given that Daniel appears to have a United States focus but does not explicitly limit himself geographically, pitches should take into account their relevance within the US market while also being mindful that international developments may also be relevant if they have implications for US-based companies or regulations.

This information evolves through artificial intelligence and human feedback. Improve this profile .

Journalists With Similar Coverage:

Based on similarity of content.
Most recent topics
Not enough data
Most recent topics
Not enough data
Most recent topics
Not enough data
Adam Feuerstein
Senior Writer, National Biotech Columnist
Publications
Most recent topics
Not enough data
Most recent topics
Not enough data